The potassium-sparing diuretic spironolactone is a viable treatment option in women with a previous breast cancer diagnosis .
In daily practice, spironolactone is often used off-label for the treatment of androgenetic alopecia in women. The agent exerts competitive blockade on androgen receptors in target tissues. It has been shown to arrest hair loss progression; a significant percentage of women even achieve partial hair regrowth . However, limited data is available on its safety in breast cancer survivors. Due to its estrogenic effects, a potential risk for promoting cancer recurrence has been discussed. To clarify this issue, the authors performed a retrospective analysis using the Humana Insurance database.
Breast cancer survivors were identified using ICD-9/10 codes and divided into cohorts by spironolactone prescription. Patient demographics and comorbidities were compared and analysed. Cohorts with and without spironolactone use were f...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Better compliance in AD skin care with novel emollient stick Next Article
Baricitinib beneficial in head and neck AD »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.